LONG MINI-FUTURE - GENMAB | Delayed Börse Stuttgart 02:55:19 2024-06-04 EDT | ||
| 14.48 EUR | -2.62% |
|
| Current month | +3.35% | ||
| 1 month | +1.97% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-04 | 14.48 | -2.62% |
| 24-06-03 | 14.87 | +6.14% |
| 24-05-31 | 14.01 | +1.08% |
| 24-05-30 | 13.86 | -0.43% |
| 24-05-29 | 13.92 | -2.86% |
Delayed Quote Börse Stuttgart
Last update June 04, 2024 at 02:55 am
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VA8VDL |
| ISIN | DE000VA8VDL2 |
| Date issued | 2018-10-26 |
| Strike | 866.7 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.34 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 33.85 € |
|---|---|
| Lowest since issue | 1.71 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,938
DKK
Average target price
2,464
DKK
Spread / Average Target
+27.17%
- Stock Market
- Certificates
- Certificat
